导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -9.88% | 3737/4773 |
| 近一周 | -2.76% | 3015/5462 |
| 近一月 | -2.80% | 1410/5421 |
| 近一季 | -1.12% | 942/5209 |
| 近半年 | -5.74% | 2938/4920 |
| 近一年 | -14.80% | 3659/4366 |
| 近两年 | 30.96% | 2234/2954 |
| 近三年 | 17.96% | 1549/2253 |
| 成立以来 | -0.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.20% 4217/4961 |
-8.95% 3933/5312 |
- - |
- - |
| 2025 | 27.32% 1566/4813 |
15.76% 160/3635 |
3.72% 958/4076 |
14.49% 2901/4524 |
-7.37% 3791/4813 |
| 2024 | 10.57% 1401/3463 |
-5.88% 1964/2808 |
3.72% 253/3014 |
17.99% 1080/3129 |
-4.01% 2417/3463 |
| 2023 | -14.33% 1595/2656 |
-3.06% 2064/2280 |
-1.12% 446/2385 |
-8.43% 1699/2515 |
-2.40% 470/2655 |
| 2022 | -9.70% 181/2207 |
-9.85% 356/1919 |
6.96% 566/2016 |
-17.10% 1552/2113 |
12.97% 112/2208 |
| 2021 | -14.44% 1148/1822 |
2.21% 225/1255 |
2.06% 1017/1330 |
-11.83% 1278/1466 |
-6.97% 1559/1822 |
| 2020 | 8.18% 858/1250 |
-12.89% 904/1028 |
11.14% 745/1067 |
0.23% 1042/1164 |
11.48% 536/1184 |
| 2019 | 11.93% 720/1092 |
10.63% 717/739 |
0.11% 189/788 |
-5.39% 793/850 |
6.82% 539/918 |
| 2018 | - - |
- - |
- - |
-1.09% 228/660 |
-7.26% 61/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安CES港股通ETF联接A VS. 长安沪深300非周期A(740101) |